BIOTIE THERAPIES CORP. STOCK EXCHANGE NOTICE 5 October 2011 at 9:30 a.m. (Helsinki time) Notice to Biotie shareholders on registration of merger plan and documents available for review The Boards of Directors of Biotie Therapies Corp. ("Biotie" or the "Company") and Newron Pharmaceuticals S.p.A. ("Newron"), have on 27 September 2011 signed a merger plan (the "Merger Plan"), according to which Newron will merge into Biotie and all of its all assets and liabilities will transfer to Biotie and the shareholders of Newron will receive new Biotie shares and options and a receivable intended to be used to pay the subscription price for Biotie shares subscribed based on such options as merger consideration (the "Merger"). The Merger Plan has today been registered with the Finnish Trade Register. This notice is the notice to the Company's shareholders pursuant to Chapter 16, Section 10(3) of the Finnish Companies Act. The grounds for the Merger and its planned timetable have been described in the stock exchange release issued by Biotie on 27 September 2011. The following documents relating to the Merger are available for review on the Company's website as of today: (i) the Merger Plan and its appendices, (ii) the report of Biotie's Board of Directors on the Merger, (iii) the statement of the independent expert jointly appointed by Biotie and Newron on the Merger, (iv) the Company's financial statements, annual reports and auditor's reports for the financial years 2008-2010 and its interim reports for the periods 1 January to 31 March 2011 and 1 January to 30 June 2011, (v) Newron's financial statements, annual reports and auditor's reports for the financial years 2008-2010 and its interim report for the period 1 January to 30 June 2011, (vi) Minutes of the general meetings of shareholders of Biotie and Newron after the end of the last financial period (31 December 2010), (vii) a statement by the Board of Directors of the Company on the events that have occurred after the interim report for the period 1 January to 30 June 2011 and that have an essential effect on the state of the Company, and (viii) a statement by the Board of Directors of Newron on the events that have occurred after the interim report for the period 1 January to 30 June 2011 and that have an essential effect on the state of Newron. In Turku, 5 October 2011 Biotie Therapies Corp. Board of Directors For further information, please contact: Virve Nurmi, Investor Relations Manager tel. +358 2 274 8911, e-mail: virve.nurmi@biotie.com www.biotie.com Distribution: NASDAQ OMX Helsinki Ltd Main Media [HUG#1552250]
Notice to Biotie shareholders on registration of merger plan and documents available for review
| Source: Biotie Therapies